Clal Biotech, Hyperion seek settlement over Andromeda
– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. – Clal Biotechnology (TASE: CBI), managed by Reuven Krupik, and More...
Wednesday 03 March, 2021
- Ella Emhoff Teams With Batsheva Hay for New Fashion Line
- CBD's Future as an Active Ingredient in Therapeutic Medicine
- 6 Most Valuable Israeli Companies – All Above $10 Billion in Stock
- Now Even Dr. Seuss Has Gotten Canceled – 6 of His Books Now Removed
- Curv Digital Asset Startup Looking to $200 Million Exit